Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
55.94
+1.22 (2.23%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Vaxcyte Employees
Vaxcyte had 507 employees as of December 31, 2025. The number of employees increased by 93 or 22.46% compared to the previous year.
Employees
507
Change (1Y)
93
Growth (1Y)
22.46%
Revenue / Employee
n/a
Profits / Employee
-$1,512,087
Market Cap
8.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 507 | 93 | 22.46% |
| Dec 31, 2024 | 414 | 160 | 62.99% |
| Dec 31, 2023 | 254 | 96 | 60.76% |
| Dec 31, 2022 | 158 | 69 | 77.53% |
| Dec 31, 2021 | 89 | 31 | 53.45% |
| Dec 31, 2020 | 58 | 15 | 34.88% |
| Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Nuvalent | 228 |
PCVX News
- 18 hours ago - Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - GlobeNewsWire
- 5 days ago - Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate - GlobeNewsWire
- 27 days ago - Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - GlobeNewsWire
- 5 weeks ago - Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - GlobeNewsWire
- 6 weeks ago - Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 7 weeks ago - Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire